Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MECP2 | P51608 | 3/20 | 0.54 |
| ▸ | MBD2 | Q9UBB5 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 7/20 | 0.47 |
| ▸ | NPC1 | O15118 | 6/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 6/20 | 0.44 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2108704 | 0.76 | MECP2 (0.49) | MECP2MBD2RAB9ANPC1POLB | |
| SCHEMBL12692361 | 0.71 | MECP2 (1.00) | MECP2MBD2RAB9ANPC1POLB | |
| SCHEMBL1754414 | 0.69 | NR1H2 (0.89) | NR1H2NR1H3 | |
| SCHEMBL1754234 | 0.69 | NR1H2 (0.64) | NR1H2NR1H3 | |
| SCHEMBL10647186 | 0.69 | NR1I2 (0.37) | KMT2ANR1H2NR1H3SMN1; SMN2KDM4E | |
| SCHEMBL1754040 | 0.69 | NR1H2 (0.62) | NR1H2NR1H3 | |
| SCHEMBL1753982 | 0.69 | NR1H2 (0.71) | NR1H2NR1H3 | |
| SCHEMBL1753945 | 0.68 | NR1H2 (0.61) | NR1H2NR1H3 | |
| SCHEMBL1754398 | 0.68 | NR1H2 (0.65) | NR1H2NR1H3 | |
| SCHEMBL1754303 | 0.68 | NR1H2 (0.64) | NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130345220-A1 | COMPOUNDS AND COMPOSITIONS AS LXR MODULATORS | IRM LLC (BM) | 2013-12-26 | — | — | US | disclosed |
| US-8569345-B2 | Compounds and compositions as LXR modulators | MOLTENI VALENTINA (US) | 2013-10-29 | — | — | US | disclosed |
| US-20120214812-A1 | COMPOUNDS AND COMPOSITIONS AS LXR MODULATORS | IRM LLC (BM) | 2012-08-23 | — | — | US | disclosed |
| US-8158662-B2 | Compounds and compositions as LXR modulators | HAMILTON (BM) | 2012-04-17 | — | — | US | disclosed |
| US-20090325981-A1 | Compounds and compositions as lxr modulators | IRM LLC (BM) | 2009-12-31 | — | — | US | disclosed |
| EP-1713799-A2 | COMPOUNDS AND COMPOSITIONS AS LXR MODULATORS | IRM, LLC (BM) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005077124-A2 | COMPOUNDS AND COMPOSITIONS AS LXR MODULATORS | IRM LLC (BM) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130345220-A1 | COMPOUNDS AND COMPOSITIONS AS LXR MODULATORS | NR1H2, NR1H3, NR1H4 | MECP2 3417/4885MBD2 3752/4885RAB9A 2722/4885 |
| US-20090325981-A1 | Compounds and compositions as lxr modulators | NR1H2, NR1H3, NR1H4 | MECP2 3417/4885MBD2 3752/4885RAB9A 2722/4885 |
| US-20120214812-A1 | COMPOUNDS AND COMPOSITIONS AS LXR MODULATORS | NR1H2, NR1H3, NR1H4 | MECP2 3417/4885MBD2 3752/4885RAB9A 2722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.